Clinical Trial Update: Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of Rucaparib plus Pembrolizumab as maintenance therapy in Stage IV non-squamous non-small cell lung cancer was terminated, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• RUBRACA (RUCAPARIB)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Stage IV Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-02-12